Gowling WLG advises Astellas Pharma over the transfer of pain management therapy product

20 December 2016

Gowling WLG's Life Sciences team has advised Astellas Pharma Europe in an agreement to transfer the exclusive rights for Qutenza™ (capsaicin 8% patch) in Europe, Middle East and Africa to Grünenthal.

The agreement will see Astellas Pharma Europe transfer all of its commercialisation rights for Qutenza to Grünenthal and is anticipated to conclude in 2018. As part of the deal, Astellas will continue to fully support the transition to ensure that patients who rely on Qutenza for the management of their pain are unaffected by the change.

Qutenza is used for the treatment of peripheral neuropathic pain (PNP) in adults, and the agreement means patients will be able to benefit from continued access and support to this vital treatment.

Gowling WLG has worked with Astellas for more than seven years and the deal showcases the law firm's extensive experience in the Life Sciences sector, in particular in relation to the disposal of marketed products (such as acting for AstraZeneca on the divestment of Caprelsa to Genzyme). Partners Luke Kempton and Ian Piggin led the deal for Gowling WLG, and Veronika Hughes-Bednar led Astellas' in house team in relation to the complex sale of the Qutenza™ assets.

Luke Kempton commented: "We always enjoy working with Astellas and we're delighted with the outcome for them."

Ian Piggin added: "This deal highlights our expertise in relation to the disposal of marketed products in the life sciences sector."

Related   Life Sciences